Literature DB >> 9511823

The rapid diagnosis of isoniazid and rifampicin resistance in Mycobacterium tuberculosis--a molecular story.

F A Drobniewski1, S M Wilson.   

Abstract

Isoniazid and rifampicin resistance are assayed phenotypically by the resistance ratio, absolute concentration or proportion methods. Assay methods are often difficult to standardise and the World Health Organization (WHO) Global Programme on Drug Resistance is attempting to produce standardised drug resistance data worldwide. Broth-based methods are faster than solid media systems, and a commercial radiometric system, the Bactec 460, is arguably the fastest method and permits testing to be completed within 7-14 days; however, this method is expensive and requires disposal of radioactive material. Novel phenotypic methods that utilise mycobacteriophages have shown promise. Other molecular detection systems require knowledge of the genes encoding the drug target (the inhA/mabA, katG, oxyR and ahpC genes for isoniazid; rpoB for rifampicin) and the mutations producing resistance. These genotypic methods are limited in that not all resistance mechanisms are known, but advanced assays for rifampicin resistance that use gene sequencing, heteroduplex analysis, solid-phase hybridisation or single-strand conformation polymorphism analysis are becoming available.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9511823     DOI: 10.1099/00222615-47-3-189

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  33 in total

Review 1.  Tuberculous meningitis.

Authors:  G Thwaites; T T Chau; N T Mai; F Drobniewski; K McAdam; J Farrar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

Review 2.  Modern laboratory diagnosis of mycobacterial infections.

Authors:  S A Watterson; F A Drobniewski
Journal:  J Clin Pathol       Date:  2000-10       Impact factor: 3.411

3.  Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from Brazil.

Authors:  A R Valim; M L Rossetti; M O Ribeiro; A Zaha
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

4.  Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis clinical isolates from India.

Authors:  C Mani; N Selvakumar; S Narayanan; P R Narayanan
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

Review 5.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

6.  Characterization of rpoB mutations in rifampin-resistant clinical isolates of Mycobacterium tuberculosis from Turkey by DNA sequencing and line probe assay.

Authors:  Cengiz Cavusoglu; Suleyha Hilmioglu; Sevinc Guneri; Altinay Bilgic
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

7.  Mutations in the rpoB gene of multidrug-resistant Mycobacterium tuberculosis isolates from China.

Authors:  Jun Yue; Wei Shi; Jingping Xie; Yao Li; Erliang Zeng; Honghai Wang
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

8.  Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil.

Authors:  Rosilene Fressatti Cardoso; Robert C Cooksey; Glenn P Morlock; Patricia Barco; Leticia Cecon; Francisco Forestiero; Clarice Q F Leite; Daisy N Sato; Maria de Lourdes Shikama; Elsa M Mamizuka; Rosario D C Hirata; Mario H Hirata
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

9.  Evaluation of GenoFlow DR-MTB Array Test for Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis.

Authors:  B Molina-Moya; G Kazdaglis; A Lacoma; C Prat; A Gómez; R Villar-Hernández; E García-García; L Haba; J Maldonado; S Samper; J Ruiz-Manzano; J Domínguez
Journal:  J Clin Microbiol       Date:  2016-02-10       Impact factor: 5.948

10.  Diagnosing multidrug resistant tuberculosis in Britain. Clinical suspicion should drive rapid diagnosis.

Authors:  F A Drobniewski
Journal:  BMJ       Date:  1998-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.